Aurobindo Pharma informs about disclosure

07 Sep 2023 Evaluate
Pursuant to Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 and further to the above referred letter, Aurobindo Pharma has informed that the United States Food and Drug Administration (US FDA) inspected the Company’s Unit III, a Formulation manufacturing facility situated at Bachupally Village, Medchal Malkajgiri District, Telangana, from July 14 to July 21, 2023. The Unit has now received an Establishment Inspection Report classifying the facility as ‘Voluntary Action Indicated’ (VAI).

The above information is a part of company’s filings submitted to BSE.

Aurobindo Pharma Share Price

1223.65 3.45 (0.28%)
22-Nov-2024 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1797.80
Dr. Reddys Lab 1213.90
Cipla 1486.30
Lupin 2069.95
Zydus Lifesciences 948.70
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.